SLC2A1 and glioblastoma: Furthermore, combining BAY-876 with the PD-1/PD-L1 blocker BMS-1 resulted in an even greater extension of survival, indicating a potential synergistic effect between GLUT1 inhibition and immune checkpoint blockade in the treatment of GBM [56].